SK Chemical will sell Zemplar

The original Zemplar (Paricalcitol) will be sold by SK Chemical in Korea.

 

It is imported and supplied by AbbVie Korea, and SK Chemical has been in charge of distribution, sales and marketing in Korea since July.

 

SK Chemical is expected to compete fiercely with generic companies.

 

According to industries on the 12th, SK Chemical has been distributing and selling AbbVie's Zemplar in Korea since July.

 

Sales of Zemplar ampules, which had previously been distributed, were discontinued.

 

Zemplar is used to treat and prevent secondary parathyroidism associated with chronic renal failure.

 

It is especially used to treat complications in dialysis patients.

 

Last year, IQVIA was sold at ₩7.9 billion, which is widely used in dialysis complications markets along with Kyowa Kirin Korea's Regpara.

 

Last year, generic for Zemplar was launched for the first time in Korea.

 

Boryung's Pacitol was granted permission on January 30 last year.

 

Pacitol has been on sale since April of that year.

 

As of last year's IQVIA, sales amounted to ₩1.3 billion.

 

Since then, Huons' Hucitol has expanded its consignment production with permission.

 

This change in Zemplar's domestic sales company is interpreted as a response to the generic's offensive.

 

Its strategy is to win the competition with Generic through SK Chemical, which has a well-established distribution network in Korea.

 

The reason why the ampule formulation was discontinued is because of the lower price due to the launch of generic products.

 

Zemplar ampule formulation was twice as expensive as vial formulation, but since April, when generic items were released, both original and generic have become the same price.

 

As a result, competition between original and generic companies is expected to intensify.